Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960055 | 0.91 | EPHX2 (0.43) | EPHX2MAPK14FLT3LMNA | |
| SCHEMBL4603694 | 0.90 | MAPK14 (0.53) | EPHX2MAPK14MAPK11MAPTMAPK13 | |
| SCHEMBL2948049 | 0.87 | MAPK14 (0.49) | MAPK14MAPK11MAPTFLT3MAPK13 | |
| SCHEMBL4604121 | 0.84 | MAPK14 (0.53) | MAPK14MAPK11MAPK13ERBB2LMNA | |
| SCHEMBL4604376 | 0.79 | PRKAA2 (0.56) | EPHX2MAPK14MAPK11MAPTMAPK13 | |
| SCHEMBL2951799 | 0.79 | NTRK1 (0.42) | MAPK14MAPK11MAPTFLT3MAPK13 | |
| SCHEMBL4604914 | 0.77 | MAPK14 (0.49) | MAPK14MAPK11MAPTMAPK13MAPK12 | |
| SCHEMBL6143107 | 0.76 | MAPK14 (0.55) | MAPK14MAPK11MAPTMAPK13MAPK12 | |
| SCHEMBL2955221 | 0.76 | MAPK14 (0.47) | MAPK14MAPK13 | |
| SCHEMBL4601384 | 0.76 | MAPK14 (0.61) | MAPK14MAPK11MAPTMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1761520-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | TNF, TNFRSF1A, IL2 | EPHX2 2089/4885MAPK14 436/4885MAPK11 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.